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Abstract
Background: Heavy menstrual bleeding is an important health problem. Two frequently used therapies are the
levonorgestrel intra-uterine system (LNG-IUS) and endometrial ablation. The LNG-IUS can be applied easily by the
general practitioner, which saves costs, but has considerable failure rates. As an alternative, endometrial ablation
is also very effective, but this treatment has to be performed by a gynaecologist. Due to lack of direct comparison
of LNG-IUS with endometrial ablation, there is no evidence based preferred advice for the use of one of these
treatment possibilities.
Method/design: A multicenter randomised controlled trial, organised in a network infrastructure in the
Netherlands in which general practitioners and gynaecologists collaborate.
Women ≥ 34 years with heavy menstrual bleeding, a Pictorial Blood Assessment Chart (PBAC) score exceeding
150 points and no future child wish can participate in the trial. After informed consent, women will be
randomised to a strategy starting with a levonorgestrel releasing intrauterine system or a strategy starting with
endometrial ablation.
The primary outcome is the PBAC score at 24 months of follow-up. Secondary outcomes are patient satisfaction,
complications, number of re-interventions, menstrual bleeding pattern, quality of life, sexual function, sick leave
and costs. As predictors of effect of intervention we also meaure level of coagulation factors.
Discusson: This study, considering both effectiveness and cost effectiveness of LNG-IUS versus endometrial
ablation may well improve care for women with heavy menstrual bleeding.
Trial registration: Dutch trial register, number NTR2984
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Background
Heavy menstrual bleeding is a frequent problem that
affects many premenopausal women in the Netherlands
and is the most important reason for a visit a the out-
patient department of gynaecology [1,2]. Each year one in
20 women between 30 to 49 years of age consult their
general practitioner (GP) with heavy menstrual bleeding.
Hormonal treatment with the oral contraceptive pill or
the levonorgestrel releasing intra uterine system (LNG-
IUS) or non-hormonal treatment with tranexamic acid or
non-steroidal anti-inflammatory drugs (NSAID) are advised
as treatments of first choice. Nevertheless 77% of the women
are not willing to continue their treatment and often end
up undergoing other treatment or even surgery [3,4].
Hysterectomy is a definitive solution for the treatment
of heavy menstrual bleeding, and in 2010 11,038 women
underwent a hysterectomy due to bleeding disorders in
the Netherlands [5]. Recently it was reported that hys-
terectomy should be considered the preferred strategy
for the treatment of heavy menstrual bleeding based on
cost-effectiveness [6]. Nevertheless, it is a major surgical
procedure and has significant physical complications and
social and economic costs [7]. A significant number of
women with heavy menstrual bleeding who seek treatment
will not benefit from, or will not wish to continue the
medical treatment and are keen to preserve their uterus
[3,8]. Many women opt for a less invasive treatment, even
when they are informed of the fact that success is not
always assured [1,9].
Two frequently used minimally invasive treatment
options for heavy menstrual bleeding are the LNG-IUS
and endometrial ablation.
Intrauterine devices were initially introduced as contra-
ceptives, but after the addition of progestagen (LNG-IUS)
these devices also reduce menstrual bleeding effectively.
The local release of levonorgestrel in the uterine cavity
suppresses endometrial growth. A systematic review on
the effectiveness of the LNG-IUS in heavy menstrual
bleeding concluded that the reduction of menstrual
blood loss was 79-96% in the LNG-IUS group [10-13]. In
women with heavy menstrual bleeding who presented
to primary care providers, the LNG-IUS was more
effective than usual medical treatment in reducing the
effect of heavy menstrual bleeding on quality of life
[14]. However, up to 60% of women discontinue LNG-
IUS within 5 years because of unscheduled bleeding,
pain, and/or systemic progestogenic side-effects [15]. In
the Royal College of Obstetricians and Gynaecologists
(RCOG) guideline on heavy menstrual bleeding, the use
of the LNG-IUS is the first therapeutic option when
drug treatment has failed. This is not based on proven
cost-effectiveness [15].
Endometrial destruction techniques, which aim to destroy
or remove the endometrial tissue, have become alternatives
to hysterectomies. In 1991 in the Netherlands 21,433
hysterectomies were performed, a number that was re-
duced to 16,320 in 1998 and just above 11,000 in 2010,
which was partly due to the start of using endometrial
ablation [16]. Approximately 47-58% percent of women
report an amenorrhea after treatment with the bipolar
ablation device [5,17-20]. The satisfaction rates of endo-
metrial ablation have been evaluated by several random-
ised controlled trials and is showing a rate of about 90%
[19,21,22]. Ablation techniques result in shorter duration
of surgery, shorter hospital stay and quicker recovery time
compared to hysterectomy.
Seven trials compared the LNG- IUS with transcervical
resection of the endometrium or balloon abaltion. In the
meta-analyses a significant lower mean pictorial blood
chart score (PBAC) was reported for all women and a
significant lower mean reduction in pictorial blood
chart score was reported in the surgical group. One
study showed a significantly lower median PBAC score
in the LNG-IUS group at nine months and one year
follow-up 23. Further outcomes showed no difference
in satisfaction rates, amenorrhea rates, duration of men-
struation, further surgical treatment or quality of life
(QoL). Nevertheless, the studies are small, most studies
have a short period of follow-up and contain a lot of
non-compliance, which makes interpretation of out-
comes difficult [12,20,23-27].
Consequently, usual care in the Netherlands implies
one of these two strategies for the treatment of heavy
menstrual bleeding if drug therapy fails. The strategy
LNG-IUS means prescription and placement by the gen-
eral practitioner (GP) or gynaecologist without anaesthe-
sia. The strategy endometrial ablation implies performing
an endometrial ablation by a gynaecologist in day-care
or outpatient clinic with or without general anaesthesia.
Due to lack of sufficiently powered studies directly
comparing LNG-IUS with endometrial ablation, there
is currently no evidence based advice for the use of one
of these treatment possibilities.
We propose a randomised controlled trial in which
these two strategies are compared in the treatment of
heavy menstrual bleeding. The study will focus on (cost-)
effectiveness, patient satisfaction and QoL.
Methods/design
Objective
The aim of this study is to assess the effects and cost-
effectiveness of a strategy starting with LNG-IUS versus
a strategy starting with endometrial ablation in women
with heavy menstrual bleeding. This study will also
evaluate QoL, sexual function and as predictors of effect
of intervention we also measure level of coagulation
factors.
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Trial design
This study is a multicenter randomised controlled trial with
an economic evaluation alongside it. It will be performed
by the Dutch Consortium for Studies in Women’s Health
and the department of General Practice of the Univer-
sity Medical Center Groningen. The study will be orga-
nized in a network infrastructure in which GPs and
gynaecologists collaborate. Participating hospitals can be
district, teaching, third referral or university hospitals.
The study is conducted according to the principles of the
Declaration of Helsinki and in accordance with the Med-
ical Research Involving Human Subjects Act (WMO)
and has been approved by the ethics committee of the
Academic Medical Centre Amsterdam (ref. no MEC
10/183). The protocol is registered in the Dutch trial
register, number NTR2984.
Eligibility criteria
Women ≥ 34 years suffering from heavy menstrual bleed-
ing, with a PBAC score exceeding 150 points can partici-
pate in the trial.
Women who might want to get pregnant in the future
will be excluded as an endometrial ablation is an abso-
lute contraindication for pregnancies. Other exclusion
criteria are abnormal cervix cytology in the past 5 years,
a sounding length of more than 10 cm, intracavitary fi-
broids or polyps or large intramural fibroids determined
by either a transvaginal ultrasound (TVU) or a bimanual
vaginal examination.
Patient recruitment, randomization and collection of data
Eligible patients are identified by the gynaecologist in
the participating hospitals or by participating general
practitioners. Before entry into the study, inclusion and
exclusion criteria are checked by research nurses and if
women are eligible they will also be counseled by these
experienced research nurses. They will be informed
about the aims, methods, reasonably anticipated benefits
and potential hazards of the study. We will ask separate
informed consent for taking and analyzing blood on
levels of coagulation factors. After given written informed
consent women will be randomised to a strategy starting
with a LNG-IUS or a strategy starting with endometrial
ablation. Randomisation is performed by accessing a
web-based randomisation program. We will stratify for
inclusion by general practitioner or by gynaecologist.
Patients will be randomised into two groups in a ratio of
1:1, using permuted block randomization with a variable
block size.
Participants will be given a computer generated numeric
code. Data handling will be done anonymously, with the
patient code only available to the local investigator and
the research nurse working in the local centre. At the local
centres, baseline data and follow-up data collection is the
responsibility of the specialised research nurse. Data will
be collected using a website dedicated to studies in the
Dutch Consortium for women’s health and reproductive
medicine studies (www.studies-obsgyn.nl). In accordance
with guidelines of the Dutch Federation of University
Medical Centres (NFU) the data will be kept for 20 years.
Interventions
The LNG-IUS can be placed either by a GP or by a gy-
naecologist. In the endometrial ablation group, a second
generation bipolar ablation technique (Novasure) will be
performed by a gynaecologist.
Measurements and follow-up
Before randomization patients are asked to fill out a
PBAC. Prior to start of the treatment, participating patients
will fill in two questionnaires measuring health-related
QoL: the Short Form-36 (SF-36), a validated GP and
the Shaw heavy menstrual bleeding questionnaire, a
disease specific questionnaire, which we validated lin-
guistically. Furthermore, patients are asked to complete
questionnaires to measure sexual functioning: the Fe-
male Sexual Function Index (FSFI), Female Sexual Dis-
tress Scale (FSDS) and a questionnaire to measure
(indirect) costs. Baseline demographic characteristics,
medical history and menstruation pattern are recorded
in a Case Record Form (CRF).
Patients will fill in the PBAC and the same question-
naires used at baseline at 3, 6, 12 and 24 months after
randomised. Since we compare strategies starting with
LNG-IUS or endometrial ablation, patients who are not
satisfied with the (randomised) treatment effect can
choose another treatment, or opt for hysterectomy.
Nevertheless, they will be asked to complete follow-up
questionnaires.
Outcome measures
Primary outcome is the PBAC score at 24 months of
follow-up. Secondary outcomes are patient satisfaction,
complications, number of re-interventions, menstrual
bleeding pattern, including rates of amenorrhea, QoL,
sexual function, sick leave and costs and as predictors
of effect of intervention we also measure level of co-
agulation factors.
Statistical analysis
Sample size
The study is designed as a non-inferiority study. Based
on previous studies, we estimate the mean PBAC score
at 24 months of follow-up to be 50 points in the LNG-
IUS group and 40 points in the endometrial ablation
group, with a SD of 40 [23-26].
Previous studies in women with heavy menstrual
bleeding have shown that a 50 point difference in
Herman et al. BMC Women's Health 2013, 13:32 Page 3 of 5
http://www.biomedcentral.com/1472-6874/13/32
PBAC –score between treatments represents a clinically
meaningful difference in reduction of menstrual bleeding.
In our study we use a non-inferiority marge of 25 points.
With this marge and estimated mean PBAC-scores of
50 and 40 points in resp. the LNG-IUS and endometrial
ablation group, the estimated scores in both treatment
groups will be far below the upper range of normal
menstrual blood loss. Using a dropout rate of 15%, an
alpha error of 2.5% and Beta error of 20%, we need to
include 266 patients (133 patients per treatment group).
Data analysis
Data will be analysed according to the intention to treat
principle. Statistical analysis will be performed using the
software Statistical Package for the Social Sciences (SPSS,
Inc., Chicago, IL, USA).
Point estimates and 95% confidence intervals will be
calculated for different time points.
First, the treatment effect at 24 months of follow-up of
a strategy starting with LNG-IUS compared to a strategy
starting with endometrial ablation will be investi-
gated. For not normally distributed continuous vari-
ables, differences between groups will be tested with
the Mann–Whitney U test. Differences between cat-
egorical variables will be tested with the Chi-square test
or Fisher’s exact test. Secondary, to assess the treat-
ment effect over time, and the interaction of the inter-
vention effect, we will use a mixed effects model. Time
to re-intervention will be compared with Kaplan Meier
analysis and Cox regression.
The analysis of the influence of lower levels of coagu-
lation on the treatment effect of LNG-IUS and endomet-
rial ablation will be explorative.
Economic evaluation
The economic analysis will be conducted from a societal
perspective including direct medical and direct and
indirect non-medical costs. Relevant direct costs com-
ponents that will be taken into account are costs of the
LNG-IUS and endometrial ablation, interventions for
complications, hospital admission and home care, consis-
ting of both professional care as well as informal care. Sick
leave and loss of productivity at work will be taken into
account as indirect non-medical costs.
The economic evaluation will be designed as a cost-
effectiveness analysis, with the costs per treatment result-
ing in a reduction of menstrual blood loss as an outcome
measure. We will also perform a cost-utility analysis
expressing the incremental costs per Quality Adjusted
Life Years based on the SF-36. Robustness of the results
(costs and health outcomes) for various assumptions
and parameter estimates will be explored in sensitivity
analyses and visualized in ICER-graphs and cost-effective-
ness acceptability curves.
Discussion
In view of its high prevalence, an optimal treatment for
heavy menstrual bleeding is of utmost importance. Usual
care in The Netherlands implies two strategies for the
treatment of heavy menstrual bleeding if drug therapy
fails: first, there is the LNG-IUS that can be applied eas-
ily by the GP, which saves costs, but has considerable
failure rates. As an alternative, endometrial ablation is
also very effective, but this treatment has to be
performed by a gynaecologist. Large randomised con-
trolled trials comparing LNG-IUS with endometrial ab-
lation are lacking and hence no preferred advice for the
use of one of these treatment possibilities is available.
When we estimate that treatment for heavy menstrual
bleeding involves 10,000 women annually, there can be
a potential saving from implementing the best strategy
as appears from the proposed study. Therefore, a direct
comparison of both strategies on cost-effectiveness is es-
sential to determine which strategy should be advocated.
This is the first study comparing LNG-IUS and endo-
metrial ablation which will be organized in a network
infrastructure in which both GP’s and gynaecologists
collaborate. It has got the largest study population
compared to other trials and has a longterm follow-up
of 2 years. Besides the objective outcome PBAC we also
measure patient satisfaction, QoL and sexual function.
Due to this study design and outcome measures, the re-
sults will be applicable for a large group of women suffer-
ing from heavy menstrual bleeding.
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